Alexander J Lin1, Caressa Hui1, Sonika Dahiya2, Hsiang-Chih Lu2, Albert H Kim3, Jian L Campian4, Christina Tsien1, Gregory J Zipfel3, Keith M Rich3, Michael Chicoine3, Jiayi Huang5. 1. Department of Radiation Oncology, Washington University School of Medicine, St Louis, Missouri. 2. Department of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri. 3. Department of Neurosurgery, Washington University School of Medicine, St Louis, Missouri. 4. Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, Missouri. 5. Department of Radiation Oncology, Washington University School of Medicine, St Louis, Missouri. Electronic address: jiayi.huang@wustl.edu.
Abstract
PURPOSE: To evaluate the clinical outcomes of reirradiation of recurrent meningiomas and factors related to patient selection and treatment modality. METHODS AND MATERIALS: Recurrent meningioma patients who failed prior stereotactic radiosurgery (SRS) or fractionated external beam radiation therapy (EBRT) received reirradiation using either SRS or EBRT. Complete response (CR), partial response (PR), and progression after reirradiation were evaluated using the MacDonald criteria. Local control (LC), progression-free survival (PFS), and overall survival (OS) after reirradiation were analyzed using the Kaplan-Meier method. Logistic and Cox regression analyses were performed to identify factors associated with reirradiation modality and PFS, respectively. RESULTS: Forty-three patients (14 grade 1/unknown, 29 grade 2/3) were reirradiated with SRS (67%) or EBRT (33%). Median time from initial SRS/EBRT to reirradiation was 60 months (range, 7.5-202); median tumor volume at the time of reirradiation was 4.8 cm3 (range, 0.14-64). After a median radiologic follow-up of 19.4 months, the response rate (CR + PR) was 8% for grade 1 and 20% for grade 2/3 meningiomas. After 2 years, LC was 78%, PFS was 63%, and OS was 80%. Larger tumor volume and prior SRS were associated with reirradiation using EBRT. Reirradiated grade 2/3 meningiomas had significantly worse PFS than grade 1 (2-year PFS: 50% vs 92%, respectively; P = .02) but not LC (P = .11) or OS (P = .39). On multivariable analysis, worse PFS was significantly associated with grade 2/3 histology (hazard ratio, 3.92; 95% confidence interval, 1.33-11.6) as well as worse Karnofsky Performance Scale score but not reirradiation dose, volume, and modality. Grades 3 to 4 radiation necrosis developed in 4 patients (10%). CONCLUSIONS: Reirradiation of recurrent meningiomas appears to be feasible with promising clinical outcomes and an acceptable toxicity profile.
PURPOSE: To evaluate the clinical outcomes of reirradiation of recurrent meningiomas and factors related to patient selection and treatment modality. METHODS AND MATERIALS: Recurrent meningiomapatients who failed prior stereotactic radiosurgery (SRS) or fractionated external beam radiation therapy (EBRT) received reirradiation using either SRS or EBRT. Complete response (CR), partial response (PR), and progression after reirradiation were evaluated using the MacDonald criteria. Local control (LC), progression-free survival (PFS), and overall survival (OS) after reirradiation were analyzed using the Kaplan-Meier method. Logistic and Cox regression analyses were performed to identify factors associated with reirradiation modality and PFS, respectively. RESULTS: Forty-three patients (14 grade 1/unknown, 29 grade 2/3) were reirradiated with SRS (67%) or EBRT (33%). Median time from initial SRS/EBRT to reirradiation was 60 months (range, 7.5-202); median tumor volume at the time of reirradiation was 4.8 cm3 (range, 0.14-64). After a median radiologic follow-up of 19.4 months, the response rate (CR + PR) was 8% for grade 1 and 20% for grade 2/3 meningiomas. After 2 years, LC was 78%, PFS was 63%, and OS was 80%. Larger tumor volume and prior SRS were associated with reirradiation using EBRT. Reirradiated grade 2/3 meningiomas had significantly worse PFS than grade 1 (2-year PFS: 50% vs 92%, respectively; P = .02) but not LC (P = .11) or OS (P = .39). On multivariable analysis, worse PFS was significantly associated with grade 2/3 histology (hazard ratio, 3.92; 95% confidence interval, 1.33-11.6) as well as worse Karnofsky Performance Scale score but not reirradiation dose, volume, and modality. Grades 3 to 4 radiation necrosis developed in 4 patients (10%). CONCLUSIONS: Reirradiation of recurrent meningiomas appears to be feasible with promising clinical outcomes and an acceptable toxicity profile.
Authors: Michael A Mooney; Wenya Linda Bi; Jonathan M Cantalino; Kyle C Wu; Thomas C Harris; Lucas L Possatti; Parikshit Juvekar; Liangge Hsu; Ian F Dunn; Ossama Al-Mefty; Phillip M Devlin Journal: J Neurooncol Date: 2019-11-19 Impact factor: 4.130
Authors: Brandon S Imber; Brian Neal; Dana L Casey; Heba Darwish; Andrew L Lin; Oren Cahlon; Brian Chon; Henry Tsai; Eugen Hug; Yoshiya Yamada; T Jonathan Yang Journal: Int J Part Ther Date: 2019-05-01
Authors: Bhuvic Patel; Rupen Desai; Sangami Pugazenthi; Omar H Butt; Jiayi Huang; Albert H Kim Journal: Front Oncol Date: 2022-03-23 Impact factor: 6.244
Authors: Lorenzo Vagnoni; Sami Aburas; Martina Giraffa; Ivana Russo; Vito Chiarella; Sergio Paolini; Paolo Tini; Giuseppe Minniti Journal: Neurosurg Rev Date: 2022-06-04 Impact factor: 2.800